MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 578.59M
Enterprise Value 336.59M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.60
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-0.70

Trading Information

Stock Price History

Beta (3Y Monthly) 2.36
52-Week Change 314.00%
S&P500 52-Week Change 37.40%
52 Week High 37.50
52 Week Low 33.34
50-Day Moving Average 35.89
200-Day Moving Average 35.72

Share Statistics

Avg Vol (3 month) 363.08k
Avg Vol (10 day) 327.51k
Shares Outstanding 513.34M
Float 9.16M
% Held by Insiders 14.09%
% Held by Institutions 157.26%
Shares Short (Jun 14, 2019) 4269.92k
Short Ratio (Jun 14, 2019) 44.63
Short % of Float (Jun 14, 2019) 42.58%
Short % of Shares Outstanding (Jun 14, 2019) 42.02%
Shares Short (prior month May 15, 2019) 4256.49k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 310.55
Trailing Annual Dividend Yield 3182.53%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3May 26, 2017
Ex-Dividend Date 4May 30, 2017
Last Split Factor (new per old) 210/1
Last Split Date 3Sep 6, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-41.20%
Return on Equity (ttm)-83.36%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-48.97M
EBITDA -52.59M
Net Income Avi to Common (ttm)-53.44M
Diluted EPS (ttm)-2.49
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)58.47M
Total Cash Per Share (mrq)4.38
Total Debt (mrq)16.6M
Total Debt/Equity (mrq)33.90
Current Ratio (mrq)5.39
Book Value Per Share (mrq)3.67

Cash Flow Statement

Operating Cash Flow (ttm)-61.9M
Levered Free Cash Flow (ttm)-42.65M